Smith & Nephew Orthopaedics Trauma & Clinical Therapies and Q-MED AB today announced that they have formed a strategic alliance to develop and commercialize Q-MED's proprietary technology for the production of stabilized non-animal hyaluronic acid, NASHA for orthopedic uses.
Drug Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Axonics Earns FDA Premarket Approval for Sacral Neuromodulation Device
Patients no longer need to have their neurostimulator explanted before they undergo the scan.
Recro Pharma Appeal of CRL for Non-Opioid Pain Product Granted
The FDA said it would work with the company on prescribing information.
FDAnews Device Daily Bulletin
SMITH & NEPHEW AND Q-MED ENTER INTO STRATEGIC ALLIANCE IN OSTEOARTHRITIS TREATMENT
June 29, 2006
